Hong Zheng

ORCID: 0000-0001-5802-330X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics
  • Cancer Treatment and Pharmacology
  • Lung Cancer Treatments and Mutations
  • Advanced Breast Cancer Therapies
  • Laser Material Processing Techniques
  • Cancer Immunotherapy and Biomarkers
  • Genetic factors in colorectal cancer
  • DNA Repair Mechanisms
  • Breast Lesions and Carcinomas
  • Estrogen and related hormone effects
  • Cancer-related molecular mechanisms research
  • Peptidase Inhibition and Analysis
  • Monoclonal and Polyclonal Antibodies Research
  • Ovarian cancer diagnosis and treatment
  • RNA modifications and cancer
  • PARP inhibition in cancer therapy
  • MicroRNA in disease regulation
  • BRCA gene mutations in cancer
  • CAR-T cell therapy research
  • Advanced Surface Polishing Techniques
  • Radiomics and Machine Learning in Medical Imaging
  • Global Cancer Incidence and Screening
  • Epigenetics and DNA Methylation

West China Hospital of Sichuan University
2013-2025

Sichuan University
2016-2025

Nanjing University of Information Science and Technology
2023-2024

Henan University
2022-2024

Peking University Cancer Hospital
2014-2024

Changzhou No.2 People's Hospital
2024

Nanjing Medical University
2024

Peking University
2014-2024

Chinese Academy of Meteorological Sciences
2023

Beijing University of Chinese Medicine
2023

Epirubicin (EPI) is one of the most effective drugs against cancer. But acquired resistance cancer cells to EPI becoming a major obstacle for successful therapy. Recently, some studies have revealed that macroautophagy (here referred as autophagy) may protect cell from anticancer drug-induced death, so autophagy might be related development drug these reagents. However, relationship between and has yet defined. Our study showed induced in human breast MCF-7 cells. And EPI-induced protected...

10.4161/auto.7.9.16521 article EN Autophagy 2011-08-26

10.1016/j.compositesa.2010.05.017 article EN Composites Part A Applied Science and Manufacturing 2010-05-27

Background Aberrant DNA methylation patterns might be used as a biomarker for diagnosis and management of cancer patients. Methods Findings To achieve gene panel developing breast blood-based test we quantitatively assessed the proportion 248 CpG sites per sample (total 31,248 in all analyzed samples) on 10 candidate genes (APC, BIN1, BMP6, BRCA1, CST6, ESR-b, GSTP1, P16, P21 TIMP3). The number 126 samples consisting two different cohorts was (first cohort: plasma from patients normal...

10.1371/journal.pone.0016080 article EN cc-by PLoS ONE 2011-01-24

Some excellent prognostic models based on survival analysis methods for breast cancer have been proposed and extensively validated, which provide an essential means clinical diagnosis treatment to improve patient survival. To analyze follow-up data of 12119 patients, derived from the Clinical Research Center Breast (CRCB) in West China Hospital Sichuan University, we developed a gradient boosting algorithm, called EXSA, by optimizing XGBoost framework ties predict disease progression...

10.1109/tbme.2020.2993278 article EN IEEE Transactions on Biomedical Engineering 2020-05-11

BackgroundThe outcome of patients with resectable mucosal melanoma is poor. Toripalimab combined axitinib has shown impressive results in metastatic an objective response rate 48.3% and a median progression free survival 7.5 months phase 1b trial. It was hypothesized that this combination administered the neoadjuvant setting might induce pathologic melanoma, so we conducted trial.Patients methodsThis single-arm II trial enrolled melanoma. Patients received toripalimab 3 mg/kg Q2W plus 5 mg...

10.1016/j.annonc.2023.10.793 article EN cc-by-nc-nd Annals of Oncology 2023-11-01

Chinese women are seriously threatened by breast cancer with high morbidity and mortality. The lack of robust prognosis models results in difficulty for doctors to prepare an appropriate treatment plan that may prolong patient survival time. An alternative model framework predict Invasive Disease-Free Survival (iDFS) early-stage patients, called MP4Ei, is proposed. MP4Ei gives excellent performance the relapse or metastasis patients 5 years.

10.1109/tbme.2018.2882867 article EN IEEE Transactions on Biomedical Engineering 2018-11-22

Nasopharyngeal carcinoma (NPC) is a malignant tumor originating from the epithelial cells of nasopharyngeal mucosa head and neck. The role long non-coding RNA methylation in NPC has received increasing attention. Therefore, this study aims to investigate mechanism lncRNA ZFAS1 its relationship with methylation, providing evidence for targeted therapy NPC.Microarray arrays were used screen differentially expressed miRNAs normal tissues tissues. QRT-PCR was quantify ZFAS1, miR-100-3p, ATG10,...

10.1186/s13027-021-00411-1 article EN cc-by Infectious Agents and Cancer 2022-01-03

We evaluated the generalizability of a single nucleotide polymorphism (SNP), rs2046210 (A/G allele), associated with breast cancer risk that was initially identified at 6q25.1 in genome-wide association study conducted among Chinese women. In pooled analysis more than 31,000 women East-Asian, European, and African ancestry, we found positive for [ORs (95% CI) = 1.30 (1.22-1.38) 1.64 (1.50-1.80) AG AA genotypes, respectively, P trend 1.54 × 10⁻³⁰], Japanese 1.31 (1.13-1.52) 1.37 (1.06-1.76),...

10.1158/0008-5472.can-10-2733 article EN Cancer Research 2011-02-09

Abstract Background Invasion and metastasis are two important hallmarks of malignant tumors caused by complex genetic epigenetic alterations. The present study investigated the contribution aberrant methylation profiles cancer related genes, APC, BIN1, BMP6, BRCA1, CST6, ESR-b, GSTP1, P14 (ARF), P16 (CDKN2A), P21 (CDKN1A), PTEN, TIMP3 , in matched axillary lymph node comparison to primary tumor tissue adjacent normal from same breast patients identify potential candidate genes as metastatic...

10.1186/1471-2407-12-244 article EN cc-by BMC Cancer 2012-06-13

A large proportion (40-60%) of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer do not benefit from trastuzumab treatment, potentially due to the lack complement-dependent cytotoxicity (CDC) activation. In present study, effect complement decay-accelerating (CD55) and CD59 glycoprotein precursor (CD59) expression on trastuzumab-induced CDC in HER2-positive cell lines was investigated. The CD55 CD59-overexpressing SK-BR-3 BT474 were selected for...

10.3892/ol.2017.6555 article EN Oncology Letters 2017-07-08

// Ling Deng 1, * , Qianqian Lei 2, Yu Wang 1 Zhu Guiqin Xie Xiaorong Zhong Yanping Nianyong Chen 3 Yan Qiu 4 Tianjie Pu Hong Bu and Zheng Laboratory of Molecular Diagnosis Cancer, Clinical Research Center for Breast, State Key Biotherapy, National Collaborative Innovation West China Hospital, Sichuan University, Chengdu, 2 Department Radiation Oncology, Chongqing Cancer Institute & Hospital Center, Chongqing, center, Pathology, These authors share co-first authorship Correspondence to:...

10.18632/oncotarget.21561 article EN Oncotarget 2017-10-06

Pterostilbene (PT) exerts antidiabetic effects by decreasing blood glucose and modulating lipid metabolism has been shown to attenuate myocardial ischemia-reperfusion (IR) injury in non-diabetic subjects. However, whether PT can protect against IR diabetes is unknown. AMPK stimulation indispensable offering cardioprotection limiting cardiac apoptosis. Thus, we hypothesized that may confer protection via activation.Sprague-Dawley rats at eight weeks of induction (induced an intravenous dose...

10.1159/000489154 article EN cc-by-nc-nd Cellular Physiology and Biochemistry 2018-01-01

The impact of the immune landscape microenvironment on cancer progression is not well understood for triple-negative breast (TNBC). We, therefore, aimed to examine association cell enrichment scores as a proxy profiles tumor with TNBC prognosis.We included 76 patients diagnosed between 2008 2016 in West China Hospital and 158 from Cancer Genome Atlas. On basis transcriptome data, we calculated overall ImmuneScore type-specific 34 types cells, using xCell, gene signature-based method. HRs...

10.1158/1055-9965.epi-19-0469 article EN Cancer Epidemiology Biomarkers & Prevention 2019-09-18
Coming Soon ...